Clinical Trials Logo
  1. Home
  2. Alpha 1-Antitrypsin Deficiency
  3. NCT00067756

4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?

Alpha 1-Antitrypsin Deficiency Clinical Trial

Official title:
"4 Phenyl Butyrate Mediated Secretion Rescue in Alpha 1-Antitrypsin Deficient Individuals"

Clinical Trial Summary

The purpose of this study is to find out whether 4-PBA will increase the level of AAT in persons with AAT deficiency whether or not they have liver disease.

Clinical Trial Description

The purpose of this study is to determine whether 4-PBA will significantly increase serum Z AAT levels in AAT-deficient individuals with and without evidence of hepatocellular injury and to assess its effects on liver injury. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00067756
Study type Interventional
Source University of Florida
Contact
Status Completed
Phase Phase 2
Start date November 2001
Completion date October 2003
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT03285100 - The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation N/A
Completed NCT03636347 - A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Phase 2
Completed NCT00396006 - Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor) Phase 4
Completed NCT04174118 - Study of DCR-A1AT in Healthy Adult Volunteers Phase 1
Completed NCT05579431 - A Phase 1, First-in-human Study of VX-634 Phase 1
Recruiting NCT05856331 - Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema Phase 2
Recruiting NCT00571272 - Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Completed NCT02168686 - Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/Phase 2
Recruiting NCT04204252 - Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD Phase 3
Completed NCT00295061 - Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 3
Completed NCT00001462 - Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals N/A
Active, not recruiting NCT05297812 - Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
Completed NCT03114020 - Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT00460096 - Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Phase 2/Phase 3
Completed NCT00377416 - Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Early Phase 1
Terminated NCT00005098 - Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency N/A
Completed NCT03362242 - Study of ARO-AAT in Normal Adult Volunteers Phase 1
Not yet recruiting NCT05897424 - Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema Phase 2
Completed NCT00301366 - The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency Phase 3